Value of Egy-Score in prediction of HCV response to sofosbuvir based therapy

Background: Liver fibrosis (LF) develops as a result of nearly all chronic liver injuries. In order to foretell the development illness and monitor effectiveness therapy interventions, it is important assess LF. The Egy-Score brand-new noninvasive score that could be utilized predict severe fibrosis. Objective: This research's objective look at whether can used non-invasive panel biomarkers for predicting response new hepatitis C antiviral treatments in Egyptian patients, determine if will affected broadly by treatment or not. Patients methods: study involved 100 HCV-infected including cirrhotic who received therapy. patients were recruited from Kafr Elsheikh institute clinic Alexandria fever hospital, Egypt, selected according protocol virus. Results: Our reported cut off baseline EGY responder non-responder studied was ≤2.92, Sensitivity 77.53, Specificity 90.91, PPV 98.6, NPV 33.3. Cut cirrhosis group